Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new dual-antibody therapy showed strong, lasting responses in patients with rare, hard-to-treat multiple myeloma.
An off-the-shelf dual-antibody immunotherapy showed deep, lasting responses in patients with extramedullary multiple myeloma, a rare and aggressive form resistant to standard treatments, according to a Mayo Clinic study published in the New England Journal of Medicine.
The therapy, which targets two proteins on cancer cells, is immediately available and does not require custom preparation.
Early results indicate significant tumor reduction and prolonged remission in some patients, offering new hope for those with limited options.
The approach, still in early trials, could transform care for this difficult-to-treat subgroup.
Una nueva terapia dual de anticuerpos mostró respuestas fuertes y duraderas en pacientes con mieloma múltiple raro y difícil de tratar.